«Малые» формы поражения шейки матки, ассоциированные с вирусом папилломы человека: диагностика, мониторинг, прогноз

1. Tang Y., Zheng L., Yang S., Li B., Su H., Zhang L.P. Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in non-vaccinated women. Virol. J. 2017; 14(1): 84.

2. Weaver B., Shew M., Qadadri B., Tu W., Tong Y., Denski C. et al. Low-level persistence of human papillomavirus 16 DNA in a cohort of closely followed adolescent women. J. Med. Virol. 2011; 83(8): 1362-9.

3. Oakeshott P., Aghaizu A., Reid F., Howell-Jones R., Hay P.E., Sadiq S.T. et al. Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. BMJ. 2012; 22(6): e3446.

4. WHO/ICO Information Centre on HPV and Cancer. Russian Federation: Human Papillomavirus and Related Cancers, Fact Sheet 2016 (2016.12.15). Available at: http://www.hpvcentre.net

5. Budak M.Ş., Senturk M.B., Kaya C., Akgol S., Bademkiran M.H., Tahaoğlu A.E. et al. A comparative study of conventional and liquid-based cervical cytology. Ginekol. Pol. 2016; 87(3): 190-3.

6. Kulasingam S.L., Havrilesky L., Ghebre R., Myers E.R. Screening for cervical cancer: a decision analysis for the U.S.: AHRQ Publication № 11-05157-EF-1. Rockville (MD): Agency for Healthcare Research and Quality; 2011. Available at: http//www.ncbi.nlm.nih.gov/books/NBK92546/pdf/Bookshelf_NBK92546.pdf

7. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. CA Cancer J Clin. 2012; 62(3): 147-72.

8. Harari A., Chen Z., Burk R.D. HPV genomics: past, present and future. Curr. Probl. Dermatol. 2014; 45: 1-18.

9. de Villiers E.M. Cross-roads in the classification of papillomaviruses. Virology. 2013; 445(1-2): 2-10.

10. Burd E.M. Human papillomavirus laboratory testing: the changing paradigm. Clin. Microbiol. Rev. 2016; 29(2): 291-319.

11. Arbyn M., Tommasino M., Depuydt C., Dillner J. Are 20 human papillomavirus types causing cervical cancer? J. Pathol. 2014; 234(4): 431-5.

12. Halec G., Alemany L., Lloveras B., Schmitt M., Alejo M., Bosch F.X. et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J. Pathol. 2014; 234(4):441-51.

13. Wang F., Li Y., Zhou J., Xu J., Peng C., Ye F. et al. miR-375 is down-regulated in squa-mous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am. J. Pathol. 2011; 179(5): 2580-8.

14. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B. et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Retrospective International Survey and HPV Time Trends Study Group. Lancet Oncol. 2010;11(11):1048-56.

15. Guan P., Howell-Jones R., Li N., Bruni L., de Sanjosé S., Franceschi S., Clifford G.M. Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int. J. Cancer. 2012; 131(10): 2349-59.

16. Köse F.M., Naki M. Cervical premalignant lesions and their management. J. Turk. Ger. Gynecol. Assoc. 2014; 15(2): 109-21.

17. Zhang Y., Wang Y., Liu L., Guo C., Liu Z., Nie S. Prevalence of human papillomavirus infection and genotyping for population-based cervical screening in developed regions in China. Oncotarget. 2016; 7(38): 62411-24.

18. Chan P.K.S. Human papillomavirus type 58: the unique role in cervical cancers in East Asia. Cell Biosci. 2012; 2(1): 17.

19. Бестаева Н.В., Назарова Н.М., Прилепская В.Н., Трофимов Д.Ю., Бурменская О.В., Павлович С.В. Папилломавирусная инфекция, обусловленная ВПЧ 52 и 58 типов, ее роль в развитии цервикальных интраэпителиальных неоплазий. Акушерство и гинекология. 2013; 7: 45-50.

20. Kim Y.S., Lee S., Zong N., Kahng J. Clinical progress of human papillomavirus genotypes and their persistent infection in subjects with atypical squamous cells of undetermined significance cytology: Statistical and latent Dirichlet allocation analysis. Exp. Ther. Med. 2017; 13(6): 3032-8.

21. Weaver B., Shew M., Qadadri B., Tu W., Tong Y., Denski C. et al. Low-level persistence of human papillomavirus 16 DNA in a cohort of closely followed adolescent women. J. Med. Virol. 2011; 83(8): 1362-9.

22. Zhao J., Guo Z., Wang Q., Si T., Pei S., Wang C. et al. Human papillomavirus genotypes associated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan, China. Infect. Agent. Cancer. 2017; 12: 8.

23. Chen H.C., Schiffman M., Lin C.Y., Pan M.H., You S.L., Chuang L.C. et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. CBCSP-HPV Study Group. J. Natl. Cancer Inst. 2011; 103(18): 1387-96.

24. Xiao S.S., Fan J.L., He S.L., Li Y.R., Wang L.Y., Yu K.N. et al. Analysis of human papillomavirus infection in 16,320 patients from a gynecology clinic in Central South China. J. Low. Genit. Tract Dis. 2016; 20(4): 327-31.

25. Wright T.C., Stoler M.H., Behrens C.M., Sharma A., Zhang G., Wright T.L. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 2015; 136(2): 189-97.

26. Huh W.K., Ault K.A., Chelmow D., Davey D.D., Goulart R.A., Garcia F.A. et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol. Oncol. 2015; 136(2): 178-82.

27. Nygård M., Røysland K., Campbell S., Dillner J. Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme. BMJ Open. 2014; 4(1): e003460.

28. Vasiljević N., Scibior-Bentkowska D., Brentnall A.R., Cuzick J., Lorincz A.T. Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol. Oncol. 2014; 132(3): 709-14.

29. Katki H.A., Schiffman M., Castle P.E., Fetterman B., Poitras N.E., Lorey T. et al. Five-year risk of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J. Low. Genit. Tract Dis. 2013; 17(5, Suppl. 1): S36-42.

30. Gage J.C., Hunt W. C., Schiffman M., Katki H.A., Cheung L.C., Cuzick J. et al. Risk stratification using human papillomavirus testing among women with equivocally abnormal cytology: results from a state-wide surveillance program. Cancer Epidemiol. Biomarkers Prev. 2016; 25(1): 36-42.

31. Ryu K.J., Lee S., Min K.J., Hong J.H., Song J.Y., Lee J.K., Lee N.W. Management of atypical squamous cells of undetermined significance of low-grade squamous intraepithelial lesions of the uterine cervix with human papilloma virus infection among young women ages less than 25 years. Diagn. Cytopathol. 2016; 44(12): 959-63.

32. Arbyn M., Xu L., Verdoodt F., Cuzick J., Szarewski A., Belinson J.L. et al. Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis. Ann. Intern. Med. 2017; 166(2): 118-27.

33. Ciavattini A., Clemente N., Tsiroglou D., Sopracordevole F., Serri M., Delli Carpini G. et al. Follow up in women with biopsy diagnosis of cervical low-grade squamous intraepithelial lesion (LSIL): how long should it be? Arch. Gynecol. Obstet. 2017; 295(4): 997-1003.

34. Tropé A., Sjøborg K.D., Nygård M., Røysland K., Campbell S., Alfsen G.C., Jonassen C.M. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds. J. Clin. Microbiol. 2012; 50(6): 1927-35.

35. Darragh T.M., Colgan T.J., Cox J.T., Heller D.S., Henry M.R., Luff R.D. et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J. Low. Genit. Tract Dis. 2012; 16(3): 205-42.

36. Agodi A., Barchitta M., Quattrocchi A., Maugeri A., Vinciguerra M. DAPK1 Promoter methylation and cervical cancer risk: a systematic review and a meta-analysis. PLoS One. 2015; 10(8): e0135078.

37. Siegel E.M., Riggs B.M., Delmas A.L. Quantitative DNA methylation analysis of candidate genes in cervical cancer. PLoS One. 2015; 10(3):e0122495.

38. Бурменская О.В., Назарова Н.М., Прилепская В.Н., Мзарелуа Г.М., Бестаева Н.В., Трофимов Д.Ю., Сухих Г.Т. Прогнозирование риска развития и прогрессирования интраэпителиальных неоплазий, ассоциированных с папилломавирусной инфекцией. Акушерство и гинекология. 2016; 2: 92-8. http://dx.doi.org/10.18565/aig.2016.2.92-98

39. Heng Z.M., Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim. Biophys. Acta. 2011; 1809(11): 668-77.

40. Мынбаев О.А., Елисеева М.Ю., Доорбар Дж., Манухин И.Б. Эпидемиология, молекулярная биология, патофизиология и принципы иммунотерапии папилломавирусной инфекции. Вопросы гинекологии, акушерства и перинатологии. 2009; 8(3): 69-79.

41. Шварц Г.Я., Прилепская В.Н., Мынбаев О.А. Изопринозин в лечении папилломавирусной инфекции в гинекологической практике. М.: ПромоушнМикс; 2011. 84с.

42. Кедрова А.Г., Леваков С.А., Челнокова Н.Н., Кожурина Е.В., Левакова С.Е., Саркисова А.А. Роль профилактических осмотров и первичного приема врача в женской консультации в выявлении субклинических и латентных форм папилломавирусной инфекции шейки матки и их мониторинг. Гинекология. 2011; 14(1): 75-81.

Поступила 16.06.2017

Принята в печать 23.06.2017